Mohamed Benlazar, Professor of Hematology at Sidi Bel Abbès University Hospital, shared a post on X:
“Ziftomenib combined with venetoclax/azacitidine in patients with R/R AML with NPM1 mutations or KMT2A rearrangements.”
Mohamed Benlazar, Professor of Hematology at Sidi Bel Abbès University Hospital, shared a post on X:
“Ziftomenib combined with venetoclax/azacitidine in patients with R/R AML with NPM1 mutations or KMT2A rearrangements.”
